Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

218
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
218
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.1K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

2.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.8K
Liver Physiology01:30

Liver Physiology

1.5K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
1.5K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

186
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
186
Obesity01:24

Obesity

660
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
660

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early-Life Nutritional Determinants of Pediatric MASLD.

Nutrients·2025
Same author

Hepatic steatosis in postmenopausal women is characterized by distinct serum extracellular vesicle proteomic signatures.

BMC medicine·2025
Same author

Genome Assembly of <i>Arctica islandica</i>, the Longest-Lived Non-Colonial Animal Species.

Animals : an open access journal from MDPI·2025
Same author

Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.

Life science alliance·2024
Same author

Non-Cardiac Amyloidosis Findings Are Not Increased in African American Carriers of <i>TTR</i> V142I with Heart Failure and/or Arrhythmia.

Journal of personalized medicine·2024
Same author

The <i>Non-Coding RNA</i> Journal Club: Highlights on Recent Papers-13.

Non-coding RNA·2023

Related Experiment Video

Updated: Sep 29, 2025

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.3K

NAFLD in normal weight individuals.

Johanna K DiStefano1, Glenn S Gerhard2

  • 1Diabetes and Fibrotic Disease Research Unit, Translational Genomics Research Institute, Phoenix, USA. jdistefano@tgen.org.

Diabetology & Metabolic Syndrome
|March 25, 2022
PubMed
Summary
This summary is machine-generated.

Nonalcoholic fatty liver disease (NAFLD) affects lean individuals, posing similar progression risks and higher mortality despite better metabolic health. Increased awareness and research are crucial for early detection and tailored treatments in this population.

Keywords:
BMICholine deficiencyClinical outcomesGenetic variationLeanMenopauseMetabolic syndromeNAFLDNASHNonobesePrevalence

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.1K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K

Related Experiment Videos

Last Updated: Sep 29, 2025

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.3K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.1K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K

Area of Science:

  • Hepatology
  • Internal Medicine
  • Gastroenterology

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized in lean individuals.
  • Despite a healthier metabolic profile, lean individuals with NAFLD face similar disease progression risks (inflammation, fibrosis, cirrhosis) as those with obesity-related NAFLD.
  • Lean individuals may experience more severe hepatic outcomes and higher mortality rates.

Purpose of the Study:

  • To review the prevalence, characteristics, outcomes, and mortality of NAFLD in lean individuals.
  • To discuss contributing factors such as diet, genetics, menopausal status, and ethnicity.
  • To highlight the need for better screening, research, and treatment strategies for lean NAFLD.

Main Methods:

  • Literature review of existing data on NAFLD in lean populations.
  • Analysis of clinical characteristics, disease progression, and mortality.
  • Discussion of etiological factors and research gaps.

Main Results:

  • Lean individuals with NAFLD exhibit comparable risks of disease progression and mortality to obese counterparts.
  • Factors like diet, genetics, menopausal status, and ethnicity may influence NAFLD development in lean individuals.
  • Lack of screening and underrepresentation in clinical trials hinder understanding and management.

Conclusions:

  • NAFLD in lean individuals is a significant health concern requiring greater attention.
  • Further research is needed to characterize lean NAFLD, improve screening, and develop targeted therapies.
  • Increased awareness and clinical trial inclusion are essential for addressing this condition.